Haematologica (Dec 2007)

Italian blood donors with anti-HBc and occult hepatitis B virus infection

  • Paola Manzini,
  • Mauro Girotto,
  • Raffaele Borsotti,
  • Osvaldo Giachino,
  • Roberto Guaschino,
  • Maurizio Lanteri,
  • Domenico Testa,
  • Paola Ghiazza,
  • Maria Vacchini,
  • Franca Danielle,
  • Alessandra Pizzi,
  • Chiara Valpreda,
  • Franco Castagno,
  • Franco Curti,
  • Paola Magistroni,
  • Maria Lorena Abate,
  • Antonina Smedile,
  • Mario Rizzetto

DOI
https://doi.org/10.3324/haematol.11224
Journal volume & issue
Vol. 92, no. 12

Abstract

Read online

Background and Objectives Occult hepatitis B virus (HBV) infection might allow the release of viremic units into the blood supply network if blood is tested only for hepatitis B surface antigen (HBsAg). The aim of our study was to evaluate the actual prevalence, viral load and genotype of occult HBV infections among first-time blood donors in north-western Italy and to suggest a way to minimize risks of transmission of this infection.Design and Methods We assayed 6313 consecutive blood donors for antibodies to HBV core antigen (anti-HBc) in addition to mandatory screening. HBsAg-negative/anti-HBc-positive donors were assayed for antibodies to HBsAg (anti-HBs) and for HBV-DNA using COBAS Ampliscreen HBV (RocheTM) on individual donations. All HBV-DNA-positive samples underwent confirmatory testing with additional polymerase chain reaction-based assays.Results The prevalence of anti-HBc positive subjects was 4.85%. Fourteen out of 288 blood donors (4.86%) were confirmed to have circulating HBV-DNA at a low level (range 8–108 IU/mL). All viremic donors were also anti-HBs-positive.Interpretation and Conclusions We estimate that in north-western Italy up to 2298 units per million donated units from first-time donors may contain HBV-DNA. The risk of an HBV-DNA positive unit from an occult carrier being released into the blood supply is more than 100 times higher than the estimated residual risk related to the window phase of HBV infection in our country. The potential infectivity of these units is debated, but their use cannot be considered safe at least in immunocompromised patients.